RxDoctor Payments Data

Anastasia Shnitser, MD

Gastroenterology · Allentown, PANPI 1346443231

Payments from drug & device makers

$2,558in general payments, 2019–2025

Across 39 payments — averaging $65.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • Bristol Myers Squibb$326
  • Takeda Pharmaceuticals U.S.A., Inc.$311
  • Covidien LP$225
  • Johnson & Johnson$192
  • Pfizer$169
  • plus $942 from 9 others

What the payments were for

  • Speaking & faculty fees$1084%
  • Food & beverage$2,44295%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,558 in reported general payments places this provider in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$212,373
Medicare patients
458
Services billed
7,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab66$1,876,909
Skyrizi On-BodyRisankizumab-Rzaa11$235,763
Humira(Cf) PenAdalimumab14$95,159
Mesalamine36$16,059
LinzessLinaclotide13$14,617
DexilantDexlansoprazole13$3,974
Esomeprazole Magnesium18$3,081
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates42$2,779
Pantoprazole Sodium157$2,755
Omeprazole110$1,757
CholestyramineCholestyramine (With Sugar)16$1,441
Azathioprine15$924
Mercaptopurine15$765
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl21$339
Famotidine52$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$192$1,876,90966 claims
AbbVieLinzess$394$14,61713 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$311$3,97413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →